Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Cytokinetics (CYTK) reported a Q3 loss of $1.36 per share, missing the Zacks Consensus Estimate of a $1.27 loss. This is slightly worse than the $1.35 loss per share from the previous year.
November 06, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cytokinetics reported a Q3 loss of $1.36 per share, which was worse than the expected loss of $1.27 per share. This performance is slightly worse than the previous year's loss of $1.35 per share.
The reported loss per share was worse than both the consensus estimate and the previous year's performance, indicating potential negative sentiment and pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100